Fluidigm (FLDM) Announces Earnings Results

Fluidigm (NASDAQ:FLDM) issued its earnings results on Thursday. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02), Bloomberg Earnings reports. Fluidigm had a negative return on equity of 134.35% and a negative net margin of 68.27%. The business had revenue of $27.75 million during the quarter, compared to the consensus estimate of $27.14 million. During the same period in the prior year, the business earned ($0.32) EPS. The business’s revenue was up 10.6% on a year-over-year basis.

Shares of Fluidigm (NASDAQ FLDM) traded up $0.80 during midday trading on Friday, reaching $6.58. 703,315 shares of the company’s stock were exchanged, compared to its average volume of 170,898. The company has a quick ratio of 2.46, a current ratio of 3.02 and a debt-to-equity ratio of 5.00. Fluidigm has a 1 year low of $2.52 and a 1 year high of $7.05. The company has a market capitalization of $289.50, a PE ratio of -3.46 and a beta of 3.24.

In other Fluidigm news, insider Levin Capital Strategies, L.P. bought 6,880 shares of the business’s stock in a transaction on Friday, November 17th. The shares were purchased at an average price of $5.05 per share, with a total value of $34,744.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 482,624 shares of company stock worth $2,917,895 in the last three months. 4.70% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Fluidigm stock. State Street Corp grew its holdings in shares of Fluidigm Co. (NASDAQ:FLDM) by 6.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 499,524 shares of the medical research company’s stock after buying an additional 29,110 shares during the period. State Street Corp owned 1.70% of Fluidigm worth $2,017,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 93.83% of the company’s stock.

A number of equities analysts have issued reports on FLDM shares. Piper Jaffray Companies reissued a “hold” rating and issued a $6.10 target price on shares of Fluidigm in a report on Thursday. ValuEngine raised shares of Fluidigm from a “strong sell” rating to a “sell” rating in a report on Monday, October 23rd.

WARNING: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/10/fluidigm-fldm-announces-earnings-results.html.

About Fluidigm

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Earnings History for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit